What is Alebund Pharmaceuticals?
Alebund Pharmaceuticals is dedicated to the discovery and development of innovative therapeutic solutions primarily targeting kidney diseases and their associated complications. The company's research also extends to other chronic conditions, positioning it within the critical and expanding field of biopharmaceuticals. As a clinical-stage entity, Alebund is focused on advancing its drug candidates through rigorous testing and regulatory pathways, aiming to address significant unmet medical needs in patient populations suffering from debilitating chronic illnesses.
How much funding has Alebund Pharmaceuticals raised?
Alebund Pharmaceuticals has raised a total of $184.6M across 3 funding rounds:
Series B
$60M
Other Financing Round
$54.5M
Series C
$70.1M
Series B (2021): $60M with participation from 3E Bioventures Capital, Quan Capital, Lilly Asia Ventures, Med-Fine Capital, and Sherpa Healthcare Partners
Other Financing Round (2021): $54.5M led by 3H Health Investment, Loyal Valley Capital, Morningside Ventures, and YuanBio Venture Capital
Series C (2025): $70.1M, investors not publicly disclosed
Key Investors in Alebund Pharmaceuticals
3E Bioventures Capital
3E Bioventures Capital is a venture capital firm with a science-driven approach, focusing on developing drugs for unmet medical needs. They leverage expertise, efficiency, and execution to support companies across the Pacific.
Lilly Asia Ventures
Lilly Asia Ventures is a leading biomedical venture capital firm dedicated to partnering with entrepreneurs to build companies developing breakthrough products for treating diseases and improving human health.
Loyal Valley Capital
Loyal Valley Capital is a thematic, research-oriented private equity firm known for backing prominent Chinese companies in various sectors, including biotech.
What's next for Alebund Pharmaceuticals?
With the recent influx of $70.1M in a major strategic investment, Alebund Pharmaceuticals is poised to accelerate its research and development initiatives. This substantial backing, part of its overall $184.6M in capital, suggests a move towards scaling operations, advancing clinical trials, and potentially expanding its therapeutic focus. The company's strategic positioning in the biopharmaceutical sector, particularly in addressing kidney diseases, indicates a strong potential for future growth and market impact. Future developments will likely involve key clinical milestones and potential partnerships, further solidifying its position in the competitive landscape.
See full Alebund Pharmaceuticals company page
